Trial Design

Post-approval methods for monitoring the safety of drug exposures in expectant mothers.

Researchers are turning to patient registries to fill rare-disease knowledge gaps.

Stay in the know with this list of up-to-date, commonly spoken, shortened words that are used often among clinical researchers.

A listing of organizations, colleges, and universities that offer courses specific to advancing the education of clinical research professionals.

The latest version of the glossary, providing hundreds of definitions for key terminology related to clinical research.

Find out the latest on industry organizations and what they offer as membership benefits.

The when and why of using the new RECIST 1.1 criteria without abandoning the old.

Updates on oncology trials.

How independent endpoint assessment committees can overcome imaging limitations.

Reductions in unused data will improve study performance, lower costs, and address ethical concerns.

Hear Dr. Robertson speak about the need to collaborate on discoveries for diabetes treatments in order to improve future global health.

Changing current business models with the use of new advancements for more sustainability.

Success and challenges for clinical trials that address these interrelated conditions.

Patient-level feedback from later studies provides a multitude of valuable answers to all stakeholders.

A concise look at this nontraditional approach to clinical studies that explains the how and why of it.

Understanding and using adaptive trial design to achieve the most of its available advantages.

Uses for next generation information management, called health intelligence, in research.

How simulation can help in the planning and implementation of adaptive clinical trials.

Using tumor xenograft technology in drug targets and personalized medicine.

Making adaptations to clinical trials in the early stages of research with the use of interim data.

The spirited decades-old journey of interferon alfa.

A look at the different testing methods and how the results impact drug development.

Developing and utilizing a comprehensive feasibility strategy to avoid risk and ensure the most efficient clinical trial.

Panel members discuss "Working Together to Develop Biomarkers for Safety Monitoring and Surrogate Endpoints," at IIR's Central Labs Partnering conference.

Industry professionals address the changes taking place in pharma and propose an upheaval of current business models to welcome new ones that are adapted for the ever-evolving clinical trials climate.